(Q51327505)

3 April 2018

title

Emerging drugs for biliary cancer. (English)

1 reference

3 April 2018

5

Tatsuhiro Shibata

1 reference

3 April 2018

author name string

Takuji Okusaka

1

1 reference

3 April 2018

Hidenori Ojima

2

1 reference

3 April 2018

Chigusa Morizane

3

1 reference

3 April 2018

Masafumi Ikeda

4

1 reference

3 April 2018

language of work or name

English

0 references

publication date

20 December 2013

1 reference

3 April 2018

Expert Opinion on Emerging Drugs

published in

1 reference

3 April 2018

volume

19

1 reference

3 April 2018

issue

1

1 reference

3 April 2018

page(s)

11-24

1 reference

3 April 2018

Liver flukes: the malady neglected

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.870553

Report of the 17th Nationwide Follow-up Survey of Primary Liver Cancer in Japan

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.870553

Phase II study of single-agent gemcitabine in patients with advanced biliary tract cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.870553

Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumours: a multicentre randomised phase II study - The UK ABC-01 Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.870553

Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.870553

Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.870553

Best supportive care compared with chemotherapy for unresectable gall bladder cancer: a randomized controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.870553

Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.870553

The ErbB signaling network: receptor heterodimerization in development and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.870553

Untangling the ErbB signalling network

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.870553

Clinicopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.870553

Amplification and overexpression of c-erbB-2, epidermal growth factor receptor, and c-met in biliary tract cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.870553

c-erbB-2 and c-Met expression relates to cholangiocarcinogenesis and progression of intrahepatic cholangiocarcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.870553

Gene amplification and mRNA and protein overexpression of c-erbB-2 (HER-2/neu) in human intrahepatic cholangiocarcinoma as detected by fluorescence in situ hybridization, in situ hybridization, and immunohistochemistry

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.870553

Clinicopathological significance of growth factors and their receptors as potential therapeutic targets for biliary tract carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.870553

Sequence dependence of MEK inhibitor AZD6244 combined with gemcitabine for the treatment of biliary cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.870553

The mitogen activated protein kinase signal transduction pathway: from the cell surface to the nucleus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.870553

Molecular recognitions in the MAP kinase cascades

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.870553

Targeting EGFR/HER2 pathways enhances the antiproliferative effect of gemcitabine in biliary tract and gallbladder carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.870553

Cetuximab, gemcitabine, and oxaliplatin in patients with unresectable advanced or metastatic biliary tract cancer: a phase 2 study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.870553

Multi-institutional phase II study of selumetinib in patients with metastatic biliary cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.870553

Cholangiocarcinomas in Japanese and Thai patients: difference in etiology and incidence of point mutation of the c-Ki-ras proto-oncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.870553

KRAS and PIK3CA but not BRAF genes are frequently mutated in Chinese cholangiocarcinoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.870553

Biliary tract carcinomas: from chemotherapy to targeted therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.870553

Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.870553

Mutational analysis of BRAF in gallbladder carcinomas in association with K-ras and p53 mutations and microsatellite instability.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.870553

Pharmacologic inhibitors of MKK1 and MKK2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.870553

Phosphorylation of the MAP kinase ERK2 promotes its homodimerization and nuclear translocation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.870553

Prognostic factors in node-negative intrahepatic cholangiocarcinoma with special reference to angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.870553

Hepatocyte growth factor/scatter factor mediates angiogenesis through positive VEGF and negative thrombospondin 1 regulation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.870553

Met receptor tyrosine kinase: enhanced signaling through adapter proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.870553

The Met receptor tyrosine kinase transduces motility, proliferation, and morphogenic signals of scatter factor/hepatocyte growth factor in epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.870553

Prognostic significance of overexpression of c-Met oncoprotein in cholangiocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.870553

Immunohistochemical demonstration of MET overexpression in human intrahepatic cholangiocarcinoma and in hepatolithiasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.870553

Intrahepatic cholangiocarcinoma escapes from growth inhibitory effect of transforming growth factor-beta1 by overexpression of cyclin D1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.870553

Effect of transforming growth factor-beta1 on human intrahepatic cholangiocarcinoma cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.870553

Isocitrate dehydrogenase 1 and 2 mutations in cholangiocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.870553

IDH1 and IDH2 mutations in gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.870553

IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.870553

IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.870553

Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.870553

IDH1 and IDH2: not your typical oncogenes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.870553

IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.870553

Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.870553

IDH1 mutations at residue p.R132 (IDH1(R132)) occur frequently in high-grade gliomas but not in other solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.870553

Cancer-associated IDH1 mutations produce 2-hydroxyglutarate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.870553

The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.870553

Profiling the effects of isocitrate dehydrogenase 1 and 2 mutations on the cellular metabolome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.870553

Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.870553

Identification of targetable FGFR gene fusions in diverse cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.870553

Survey of tyrosine kinase signaling reveals ROS kinase fusions in human cholangiocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.870553

Phase II study of erlotinib in patients with advanced biliary cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.870553

Preliminary experience of cetuximab in the treatment of advanced-stage biliary tract cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.870553

Phase II marker-driven trial of panitumumab and chemotherapy in KRAS wild-type biliary tract cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.870553

A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.870553

Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: a phase 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.870553

Report of a multicenter phase II trial testing a combination of biweekly bevacizumab and daily erlotinib in patients with unresectable biliary cancer: a phase II Consortium study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.870553

Sorafenib in patients with advanced biliary tract carcinoma: a phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.870553

SWOG 0514: a phase II study of sorafenib in patients with unresectable or metastatic gallbladder carcinoma and cholangiocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.870553

Ductal carcinoma in situ: dilemma or denouement.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.870553

A phase II study of sunitinib as a second-line treatment in advanced biliary tract carcinoma: a multicentre, multinational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.870553

Imatinib mesylate for palliative second-line treatment of advanced biliary tract cancer: a bicentric phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.870553

Epidemiology and molecular pathology of gallbladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.870553

Comparison of 5-fluorouracil, doxorubicin and mitomycin C with 5-fluorouracil alone in the treatment of pancreatic-biliary carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.870553

Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.870553

Mitomycin C in combination with capecitabine or biweekly high-dose gemcitabine in patients with advanced biliary tract cancer: a randomised phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.870553

A randomised phase II trial of weekly high-dose 5-fluorouracil with and without folinic acid and cisplatin in patients with advanced biliary tract carcinoma: results of the 40955 EORTC trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.870553

Phase III study of 5FU, etoposide and leucovorin (FELV) compared to epirubicin, cisplatin and 5FU (ECF) in previously untreated patients with advanced biliary cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.870553

Randomized phase II study of gemcitabine plus S-1 versus S-1 in advanced biliary tract cancer: a Japan Clinical Oncology Group trial (JCOG 0805).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.870553

A randomized phase II study of gemcitabine and S-1 combination therapy versus gemcitabine monotherapy for advanced biliary tract cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.870553

A phase I study of sorafenib, oxaliplatin and 2 days of high dose capecitabine in advanced pancreatic and biliary tract cancer: a Wisconsin oncology network study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.870553

10.1517/14728214.2014.870553

21 January 2018

Identifiers

DOI

1 reference

3 April 2018

1 reference

3 April 2018